← All FDA warning letters

FDA Warning Letter · #716475

Eli Lilly and Company — FDA Warning Letter (September 9, 2025)

Issued September 9, 2025Status: activeCenter for Drug Evaluation and Research (CDER)

In plain English

Marketing claims

FDA’s letter to Eli Lilly and Company cites false or misleading claims about tirzepatide products, which FDA says made them misbranded. The letter on fda.gov lists the specific claims.

What it means for you

This letter is about how the products were advertised. It is not a finding that a specific product or batch was contaminated or unsafe. Compounded GLP-1s are not FDA-approved, so if you use this company, ask which pharmacy makes your medication.

Primary Source

View the original FDA letter on fda.gov →

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eli-lilly-and-company-716475-09092025

Letter details

Company
Eli Lilly and Company
Letter number
#716475
Issue date
September 9, 2025
Subject
False & Misleading Claims/Misbranded

What FDA cited

FDA said a direct-to-consumer online video interview with Eli Lilly representatives, posted on a local TV station's website, promoted Zepbound while omitting its risk information and limitations of use, making it false or misleading. The video mentions LillyDirect. Lilly also did not submit it to FDA when it was first published.

What FDA warning letters mean

A warning letter is FDA's principal means of telling a company that the agency considers something it's doing — a marketing claim, a manufacturing practice, a labeling choice — to violate the Federal Food, Drug, and Cosmetic Act. Companies typically have 15 working days to respond.

A warning letter is not a recall, a criminal charge, or a finding that the company has broken the law. It is the start of a regulatory conversation. FDA may issue a close-out letter once it is satisfied that the company has corrected the cited issues.

For compounded GLP-1 telehealth providers, the most common citations involve unapproved new drug claims, misbranding, and the use of bulk drug substances not on FDA's approved list under FDCA sections 503A and 503B.

What this letter means if you use compounded GLP-1s

A warning letter is not a recall, and it does not by itself mean a product you already have is unsafe, but it does mean the FDA found problems it expects Eli Lilly and Company to fix. Compounded GLP-1s are not FDA-approved, and the rules for selling them changed when the shortages ended; our explainer on where compounded tirzepatide stands with the FDA now covers what is still allowed. How LillyDirect Foundayo handles care and pricing today is in our review of LillyDirect Foundayo.

Advertising is the subject of this letter, so it helps to know what the approved products are. Our tirzepatide overview page lists the brand-name versions FDA has reviewed, and our patient guide to compounded versus brand-name GLP-1s walks through the trade-offs between the two.

Other warning letters in our database

View the full database →

Editorial Disclaimer

FDA warning letters are public regulatory communications and do not, on their own, indicate that a company has done anything illegal. Companies often respond to warning letters with corrective action, and many letters are eventually closed out. The full text of this letter is available on fda.gov via the link above.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.